Antibody

#AtopicDermatitis#Antibody#Approved#항체#면역항체+2

Dupilumab - Discontinuation (Dupilumab - Discontinuation)

Atopic Dermatitis · Atopic Dermatitis

#AtopicDermatitis#Antibody#Approved#항체#면역항체+2

Dupilumab - Dose Reduction (Dupilumab - Dose Reduction)

Atopic Dermatitis · Atopic Dermatitis

#AtopicDermatitis#Antibody#Approved#항체#면역항체+3

Dupilumab Only Product (Dupilumab Only Product)

Atopic Dermatitis; AD · Atopic Dermatitis

AntibodystaleSanofiPhase 1

Dupilumab coformulated with berahyaluronidase alfa (Dupilumab coformulated with berahyaluronidase alfa)

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#항체#면역항체+2

AntibodystaleSanofiPhase 1

Dupilumab for MAD (Dupilumab for MAD)

Healthy Participants; Atopic Dermatitis Patients · Healthy Participants

#HealthyParticipants#Antibody#Phase1#항체#면역항체+3

AntibodystaleSanofiPhase 2

Dupilumab open label extension phase (Dupilumab open label extension phase)

Nephrotic Syndrome in Children; Nephrotic Syndrome Steroid-Dependent · Nephrotic Syndrome in Children

#NephroticSyndromeinChildren#Antibody#Phase2#항체#면역항체+3

#AtopicDermatitis#Antibody#Approved#항체#면역항체+4

Dupilumab step-down (Dupilumab step-down)

Atopic Dermatitis; Eczema, Atopic · Atopic Dermatitis

#AtopicDermatitis#Antibody#Approved#항체#면역항체+2

Dupilumab therapy (Dupilumab therapy)

Atopic Dermatitis · Atopic Dermatitis

AntibodystaleSanofiPhase 3

Dupilumab/Dupixent (Dupilumab/Dupixent)

Asthma · Asthma

#Asthma#Antibody#Phase3#항체#면역항체+2

AntibodystaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+4

AntibodystaleKyoto Breast Cancer Research Ne…Phase 2

Durvalmab&Tremelimumab&Fulvestrant (Durvalmab&Tremelimumab&Fulvestrant)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 DISCONTINUED

#UrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3

Cohort 1-3 (Durvalumab, Durvalumab (Cohort 1-3))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3

Cohort 4/5 (Durvalumab, Durvalumab (Cohort 4/5))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#Muscle-invasiveBladderCancer#Antibody#Phase2#항체#면역항체+2

Imfinzi (Durvalumab, Durvalumab (Imfinzi))

Muscle-invasive Bladder Cancer · Muscle-invasive Bladder Cancer

임상시험 1상태 DISCONTINUED

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab (Imfinzi) immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#LocallyAdvancedUnresectableorMet#Antibody#Phase2#항체#면역항체+4

for the first 8, 21-day, cycles (Durvalumab, Durvalumab (for the first 8, 21-day, cycles))

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation · Locally Advanced, Unresectable or Metast

#LocallyAdvancedUnresectableorMet#Antibody#Phase2#항체#면역항체+4

starting from cycle 9 (Durvalumab, Durvalumab (starting from cycle 9))

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation · Locally Advanced, Unresectable or Metast

AntibodystaleAstraZenecaPhase 3

durvalumab (Imfinzi, Durvalumab + Chemotherapy phase)

Advanced or Recurrent Endometrial Cancer · Advanced or Recurrent Endometrial Cancer

#AdvancedorRecurrentEndometrialCa#Antibody#Phase3#항체#면역항체+2

#BiliaryTractNeoplasms#Antibody#Phase2#항체#면역항체+3

durvalumab (Imfinzi, Durvalumab + Gem/Cis)

Biliary Tract Neoplasms; Gallbladder Cancer · Biliary Tract Neoplasms